Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
*Funding: Surgery_Surgical Technology, Minimally Invasive & Operating Room of the Future (ORF)
*Venture Capital Companies: Life Science, Health IT & Healthcare Investors
Avalon Ventures
Otonomy, Inc. (NASDAQ: OTIC)

Organization & Developments: Otonomy

Parents

2017: Otonomy restructures after Otividex flop; 1/3 of non-commercial workforce cut; shares up 1% premarket - Otonomy (NASDAQ:OTIC)
2017: Otonomy’s renaissance starts as Ménière’s disease drug clears trial
2017: VA_65--Otonomy, Inc (65IB) Contract Award 10/15/2016 65IB Drugs, Pharmaceuticals and Hematology related products Contract Award 10/15/2016
2019: Here Is Otonomy - Otonomy (NASDAQ:OTIC)
A clinical trial has been initiated in Meniere's disease patients, and future studies are being planned for acute hearing loss.
Broad applicability of this delivery and formulation technology has already been established across a number of therapeutic clas
Developing drug treatments for hearing loss and balance disorders.
Otonomy is a clinical stage biopharmaceutical company developing novel drug therapies for disorders of the inner and middle ear.
Otonomy's second product, OTO-203, is a sustained release antibiotic being developed for the treatment of otitis media.
The company's core technology is a sustained release formulation developed for optimal delivery of drugs from a single intratymp
The first, OTO-104, is a sustained release formulation of the steroid dexamethasone.